정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
2452 | Completed | A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 | SARS-CoV 2 | Drug: EIDD-2801 Drug: Placebo (PBO) |
Phase 2 | Ridgeback Biotherapeutics, LP | INDUSTRY | 204 | All | 18 Years | Benchmark Research, Colton, California, United States Valley Clinical Trials, Inc., Northridge, California, United States FOMAT Medical Research, Oxnard, California, United States Indago Research and Health Center, Inc., Hialeah, Florida, United States NOLA Research, New Orleans, Louisiana, United States University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States Duke, Durham, North Carolina, United States Wake Forest Baptist Health, Winston-Salem, North Carolina, United States Care United Research, LLC, Forney, Texas, United States Laguna Clinical Research, Laredo, Texas, United States Fred Hutch, Seattle, Washington, United States |
2451 | Recruiting | A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic | COVID | Drug: Azithromycin 500 milligram (mg) oral Tablet Drug: Placebo |
Phase 2 | Prof. Dr. Matthias Preusser | OTHER | 200 | All | 18 Years | AKH Vienna, Department for Internal Medicine I, Oncology, Vienna, Austria |
2450 | Completed | A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia | COVID-19 | Drug: Nafamostat Mesilate | Phase 2 | Chong Kun Dang Pharmaceutical | INDUSTRY | 104 | All | 18 Years | A108_02CVD2014 Site# 9, Barnaul, Russian Federation A108_02CVD2014 Site# 26, Krasnoyarsk, Russian Federation A108_02CVD2014 Site# 5, Moscow, Russian Federation A108_02CVD2014 Site# 8, Moscow, Russian Federation A108_02CVD2014 Site# 31, Ryazan, Russian Federation A108_02CVD2014 Site# 25, St. Petersburg, Russian Federation A108_02CVD2014 Site# 29, St. Petersburg, Russian Federation A108_02CVD2014 Site# 30, St. Petersburg, Russian Federation A108_02CVD2014 Site# 3, St. Petersburg, Russian Federation A108_02CVD2014 Site# 4, St. Petersburg, Russian Federation A108_02CVD2014 site#1, Ufa, Russian Federation |
2449 | Completed | A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia | COVID-19 | Drug: Nafamostat Mesilate | Phase 2 | Chong Kun Dang Pharmaceutical | INDUSTRY | 13 | All | 18 Years | Korea Cancer Center Hospital, Seoul, Korea, Republic of |
2448 | Active, not recruiting | A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection | COVID-19 | Biological: anti-SARS-CoV-2 convalescent plasma | Phase 2 | Medical College of Wisconsin, Froedtert Hospital | OTHER | 131 | All | 18 Years | Froedtert Hospital, Milwaukee, Wisconsin, United States |
2447 | Withdrawn | A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19 | COVID-19 | Drug: MRx-4DP0004 Drug: Placebo |
Phase 2 | 4D pharma plc | INDUSTRY | 0 | All | 18 Years | University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom |
2446 | Completed | A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19 | SARS-CoV-2 Infection | Drug: BTL-TML-COVID Drug: Placebo |
Phase 2 | Beech Tree Labs, Inc., Norwich Clinical Research Associates Ltd., Curavit Clinical Research | INDUSTRY | 28 | All | 40 Years | Intermountain Clinical Reserach, Draper, Utah, United States |